A generally accepted definition that reflects the evolving phenotypic spectrum of LFS is lacking and, increasingly, individuals with a pathogenic/likely pathogenic (P/LP) TP53 variant who do not meet the clinical LFS genetic testing criteria are being identified. This evidence concerns the gene TP53 and Li-Fraumeni syndrome.